Free Access
Issue
Med Sci (Paris)
Volume 28, Number 5, Mai 2012
Page(s) 449 - 453
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2012285002
Published online 30 May 2012
  1. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 ; 478 : 64–69. [CrossRef] [PubMed] [Google Scholar]
  2. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011 ; 365 : 1384–1395. [CrossRef] [PubMed] [Google Scholar]
  3. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011 ; 44 : 53–57. [CrossRef] [PubMed] [Google Scholar]
  4. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012 ; 119 : 569–572. [CrossRef] [PubMed] [Google Scholar]
  5. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2011 ; doi: 10.1038/leu.2011.321. [Google Scholar]
  6. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011 ; 365 : 2497–2506. [CrossRef] [PubMed] [Google Scholar]
  7. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011 ; 44 : 47–52. [CrossRef] [PubMed] [Google Scholar]
  8. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program 2009 : 353–361. [CrossRef] [Google Scholar]
  9. Di Ianni M, Baldoni S, Rosati E, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol 2009 ; 146 : 689–691. [CrossRef] [PubMed] [Google Scholar]
  10. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011 ; 208 : 1389–1401. [CrossRef] [PubMed] [Google Scholar]
  11. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011 ; 475 : 101–105. [CrossRef] [PubMed] [Google Scholar]
  12. Hiriart E, Gruffat H, Buisson M, et al. Interaction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA export. J Biol Chem 2005 ; 280 : 36935–36945. [CrossRef] [PubMed] [Google Scholar]
  13. Xu S, Powers MA. Nuclear pore proteins and cancer. Semin Cell Dev Biol 2009 ; 20 : 620–630. [CrossRef] [PubMed] [Google Scholar]
  14. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008 ; 452 : 230–233. [CrossRef] [PubMed] [Google Scholar]
  15. Gabut M, Samavarchi-Tehrani P, Wang X, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 2011 ; 147 : 132–146. [CrossRef] [PubMed] [Google Scholar]
  16. Luco RF, Misteli T. More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Curr Opin Genet Dev 2011 ; 21: 366–372. [CrossRef] [PubMed] [Google Scholar]
  17. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011 ; 471 : 467–472. [CrossRef] [PubMed] [Google Scholar]
  18. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012 ; 481 : 506–510. [CrossRef] [PubMed] [Google Scholar]
  19. Ebert BL. Molecular dissection of the 5q deletion in myelodysplastic syndrome. Semin Oncol 2011 ; 38 : 621–626. [CrossRef] [PubMed] [Google Scholar]
  20. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2011. [Google Scholar]
  21. Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011 ; 20 : 246–259. [CrossRef] [PubMed] [Google Scholar]
  22. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011 ; 20 : 25–38. [CrossRef] [PubMed] [Google Scholar]
  23. Yokoi A, Kotake Y, Takahashi K, et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J 2011 ; 278 : 4870–4880. [CrossRef] [PubMed] [Google Scholar]
  24. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011 ; 118 : 6904–6908. [CrossRef] [PubMed] [Google Scholar]
  25. Bernard OA, Gilliland DG, Mercher T. Activation de la voie Notch par OTT-MAL dans les leucémies aiguës mégacaryoblastiques. Med Sci (Paris) 2009 ; 25 : 676–678. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  26. Mercher T, Quivoron C, Couronné L, et al. I In cauda venenum ou de l’importance de (la) TET(2). Med Sci (Paris) 2011 ; 27 : 1064–1066. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.